# Drug of interest
My drug of interest is streptomycin.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. ABCC2 (z: 3.08)
2. MT-RNR1 (z: 2.65)
3. HLA-A (z: 2.23)
4. ABCB1 (z: 1.5)
5. ABCG2 (z: 1.19)
6. ABCC4 (z: 0.88)
7. ABCC3 (z: 0.87)
8. CDA (z: 0.78)
9. BRINP3 (z: 0.73)
10. HLA-B (z: 0.68)
11. NELL1 (z: 0.67)
12. MT-ND1 (z: 0.64)
13. PADI4 (z: 0.63)
14. SLC28A3 (z: 0.58)
15. HLA-E (z: 0.58)
16. HLA-C (z: 0.54)
17. VEGFC (z: 0.53)
18. HLA-G (z: 0.52)
19. SLCO1B1 (z: 0.49)
20. TPMT (z: 0.46)
21. ABCB4 (z: 0.46)
22. HLA-DRB1 (z: 0.42)
23. SLC28A1 (z: 0.41)
24. CTPS1 (z: 0.38)
25. HFE (z: 0.36)
26. HCP5 (z: 0.35)
27. RRM1 (z: 0.33)
28. ADORA2A-AS1 (z: 0.32)
29. C18orf56 (z: 0.32)
30. C5orf56 (z: 0.31)
31. HLA-DQB1 (z: 0.31)
32. DCK (z: 0.31)
33. SLCO1A2 (z: 0.31)
34. HLA-DRA (z: 0.29)
35. RUNDC3B (z: 0.28)
36. G6PD (z: 0.27)
37. MLN (z: 0.25)
38. DCTD (z: 0.25)
39. ABCC5 (z: 0.25)
40. IGF2-AS (z: 0.24)
41. SLC22A11 (z: 0.24)
42. TAPBP (z: 0.24)
43. GBP6 (z: 0.24)
44. HLA-DPB1 (z: 0.24)
45. ADA (z: 0.24)
46. SLC29A2 (z: 0.24)
47. LILRB5 (z: 0.23)
48. HLA-DRB5 (z: 0.23)
49. ABCC11 (z: 0.23)
50. SLC28A2 (z: 0.23)

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**streptomycin**: The MT-RNR1 gene, which encodes mitochondrial 12S rRNA, is associated with increased susceptibility to aminoglycoside-induced ototoxicity, influencing mitochondrial function in cochlear hair cells and heightening their vulnerability to damage from drugs like streptomycin. Additionally, the HLA-A gene, involved in immune responses, could potentially influence sensitivity to drug-induced tissue damage, although its direct role in interaction with streptomycin is less evident.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**ABCC2**: ABCC2 gene variants influence the function of the MRP2 protein, affecting the pharmacokinetics and therapeutic outcomes of various drugs. For example, genetic variations like c.1249G>A and c.3972C>T can alter the excretion and plasma concentrations of drugs such as methotrexate, mycophenolate mofetil, tacrolimus, rosuvastatin, and others including irinotecan and docetaxel, thereby impacting drug effectiveness and toxicity. Non-pharmacokinetic interactions involve drugs like clopidogrel and sorafenib, which may affect therapeutic outcomes through MRP2-related pathways.

**MT-RNR1**: The MT-RNR1 gene mutation m.1555A>G heightens susceptibility to ototoxic effects from aminoglycoside antibiotics such as gentamicin and tobramycin due to increased sensitivity of the mitochondrial ribosome, leading to impaired protein synthesis in cochlear cells and increasing the risk of irreversible hearing loss. The interaction between MT-RNR1 and aminoglycosides is pharmacodynamic as it influences the drug's action on the mitochondrial ribosome, rather than affecting the drug's metabolism or disposition.

**HLA-A**: The HLA-A gene is crucial in pharmacogenetic interactions due to its role in immune-mediated hypersensitivity reactions to certain drugs. For instance, the HLA-A*31:01 allele increases the risk of severe skin reactions to carbamazepine, while the HLA-A*02:01 allele is linked to severe adverse reactions to allopurinol, both through mechanisms involving the immune system's response to these drugs or their metabolites. Other drugs such as abacavir, phenytoin, and flucloxacillin among others are also implicated in similar immune responses based on the HLA-A gene variations, affecting drug pharmacodynamics rather than pharmacokinetics.

**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**ABCG2**: ABCG2, a gene encoding an efflux transporter, significantly influences the pharmacokinetics of various drugs by altering their absorption, distribution, and excretion, impacting the effectiveness and required dosages of medications like rosuvastatin, chemotherapy agents (topotecan, methotrexate), tyrosine kinase inhibitors (sunitinib, imatinib), antiretrovirals (tenofovir), and cardiovascular drugs (atorvastatin, apixaban). Variants such as Q141K in the ABCG2 gene can further modify these drug interactions, necessitating adjustments in drug therapies to ensure optimal efficacy and safety.

**ABCC4**: ABCC4 gene variants influence the pharmacokinetics and efficacy of various drugs by modulating their efflux from cells, which impacts drug concentrations in the body. This gene affects a wide range of drugs including cancer treatments (doxorubicin, methotrexate), antiretrovirals (zidovudine, tenofovir), and medications used in cardiovascular diseases and immune disorders (clopidogrel, azathioprine), potentially leading to variable therapy outcomes and drug resistance.

**ABCC3**: The ABCC3 gene significantly influences the pharmacokinetics and pharmacodynamics of drugs such as methotrexate and morphine by affecting their transport. Variants in ABCC3 can lead to altered excretion of methotrexate, which affects its effectiveness and side effects, and can modify the transport of morphine and its metabolites, impacting their systemic and neurological effects. Other chemotherapy drugs like doxorubicin and vincristine may also interact with ABCC3, potentially influencing drug efficacy and resistance through effects on drug efflux.

**CDA**: The activity of the CDA gene, which encodes for the enzyme cytidine deaminase, is crucial in the metabolism of some chemotherapeutic drugs, particularly nucleoside analogs like cytarabine and gemcitabine. Genetic variations in CDA can lead to different enzyme activities that affect drug concentration and active metabolite levels, thereby impacting both the efficacy and toxicity of these drugs; for example, reduced enzyme activity can increase drug plasma levels, heightening the risk of myelosuppression and hepatotoxicity.

**BRINP3**: BRINP3 is primarily involved in neural development and has a noted pharmacokinetic interaction with uric acid, possibly influencing metabolic pathways that affect uric acid levels. This interaction is significant due to its potential influence on conditions like gout or kidney diseases, although the connection is not yet well established in the literature.

**HLA-B**: The HLA-B gene plays a crucial role in drug hypersensitivity reactions through allele-specific interactions, such as the HLA-B*57:01 allele causing severe reactions to abacavir and the HLA-B*15:02 allele being associated with severe adverse reactions to carbamazepine. These interactions, which involve the immune system's response to drug-modified peptides or the drug itself presented by the HLA-B protein, emphasize the importance of genetic testing in precision medicine to tailor drug therapy and minimize adverse reactions based on individual genetic profiles.

**NELL1**: Hydrochlorothiazide, a diuretic used for managing hypertension, impacts calcium homeostasis and influences bone mineral density. Due to its effect on calcium levels, hydrochlorothiazide may affect NELL1's role in bone formation and mineralization, which are crucial for bone maintenance and development, highlighting a pharmacokinetic interaction where altered calcium availability could influence NELL1's activities.

**MT-ND1**: Genetic variations in the MT-ND1 gene, which is involved in mitochondrial energy metabolism, can enhance the risk of severe side effects when interacting with certain drugs. Antiretroviral drugs like Zidovudine may increase mitochondrial toxicity in individuals with MT-ND1 mutations, while aminoglycoside antibiotics such as gentamicin can exacerbate ototoxicity and nephrotoxicity due to their effect on mitochondrial protein synthesis. This highlights the pharmacodynamic interactions where drugs can worsen the impact of dysfunctional mitochondrial Complex I, particularly in tissues with high energy demands.

**PADI4**: Variants of the PADI4 gene may influence the effectiveness of rheumatoid arthritis treatments by affecting enzyme activities that modify drug metabolism or immune responses, potentially altering the pharmacodynamics of drugs like methotrexate. This interaction occurs through changes in immune cell function or apoptosis pathways, highlighting the pharmacogenetic significance of PADI4 in modulating responses to RA medications and inflammation pathways.

**SLC28A3**: The gene SLC28A3, which is vital for the transport of nucleoside and nucleotide analog drugs, significantly impacts the pharmacokinetics of these medications by affecting their absorption, distribution, and elimination. Specifically, it transports ara-CTP, the active metabolite of cytarabine (used in cancer chemotherapy), into cells, influencing the drug's efficacy and toxicity. This interaction suggests that variations in SLC28A3 could lead to different treatment outcomes in patients, potentially affecting the therapeutic dosing of other similar drugs used in treatments for cancers and viral infections.

**HLA-E**: The gene HLA-E, which plays a significant role in immune system regulation, may interact pharmacodynamically with methotrexate, a drug used for autoimmune diseases and cancer. This interaction likely occurs as methotrexate modulates immune responses that are under the control of HLA-E, affecting drug efficacy and potential adverse effects rather than affecting the drug's absorption, distribution, metabolism, or excretion.

**HLA-C**: HLA-C plays a crucial role in drug hypersensitivity reactions, primarily through immune response mechanisms influenced by its polymorphic nature. The presence of the HLA-C*06:02 allele, for example, is strongly associated with hypersensitivity to abacavir, used in HIV treatment, necessitating genetic screening to prevent severe reactions. Other drugs such as carbamazepine, allopurinol, clozapine, and phenytoin also show interactions with various HLA alleles that might contribute to adverse reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis.

**VEGFC**: Sorafenib, targeting RAF kinase and VEGF receptors, likely interacts with the VEGFC pathways by inhibiting receptor activity, thereby reducing tumor angiogenesis. Methotrexate, an antimetabolite, might indirectly affect VEGFC pathways by targeting rapidly dividing cells and impacting tissues where VEGFC is expressed.

**HLA-G**: HLA-G's potential pharmacodynamic interactions with drugs like fluorouracil, irinotecan, methotrexate, and capecitabine, primarily used in chemotherapy, relate to its role in modulating immune responses which could influence the immune system's ability to recognize and destroy tumor cells. These interactions likely result from HLA-G enhancing immune evasion capabilities in cancer cells, thereby potentially modifying the therapeutic efficacy of the mentioned drugs.

**SLCO1B1**: The SLCO1B1 gene, which facilitates the hepatic uptake of drugs, exhibits polymorphisms like c.521T>C that affect the pharmacokinetics of multiple drugs including statins, repaglinide, and rifampin, potentially leading to increased drug plasma concentrations, altered efficacy, and toxicity. This variability in drug transport efficiency necessitates adjustments in dosing to optimize therapeutic outcomes and minimize adverse effects for drugs such as simvastatin, atorvastatin, and others.

**TPMT**: The TPMT gene, through genetic variations like TPMT*2, TPMT*3A, and TPMT*3C, plays a significant role in influencing the metabolism of thiopurine drugs including azathioprine, mercaptopurine, and thioguanine. These variations can lead to reduced enzyme activity, thereby increasing the risk of severe myelosuppression if standard doses are used; consequently, dose adjustments based on individual TPMT activity are essential to prevent toxicity and optimize treatment efficacy.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drug’s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**HLA-DRB1**: The HLA-DRB1 gene, through its various alleles, significantly influences the pharmacogenetic interactions that affect the efficacy and safety of medications, causing immune-mediated hypersensitivity reactions. For instance, the HLA-DRB1*15:01 allele is linked to abacavir hypersensitivity in HIV treatment, while HLA-DRB1*07:01 is associated with hepatic injuries from ximelagatran, highlighting the importance of understanding a patient's HLA-DRB1 allele status to optimize and personalize treatment strategies.

**SLC28A1**: The gene SLC28A1 encodes a sodium/nucleoside cotransporter that affects the pharmacokinetics of nucleoside analog drugs such as ribavirin, zidovudine, ara-CTP, and gemcitabine by altering their absorption and cellular uptake. This interaction impacts drug concentrations in plasma and thus influences the efficacy and toxicity of therapies, particularly in antiviral and anticancer treatments.

**CTPS1**: CTPS1, important in nucleotide synthesis, impacts the metabolism and effectiveness of the chemotherapy drug ara-CTP, a cytarabine metabolite. Variations in CTPS1 activity affect the balance of nucleotides such as CTP, influencing how ara-CTP, which inhibits DNA polymerases, competes with natural nucleotides, impacting its efficacy and toxicity in cancer therapy.

**HFE**: Epoetin alfa, used for anemia in chronic kidney disease, interacts with HFE gene variants, affecting iron utilization and metabolism, thereby influencing the drug's pharmacokinetics. Conversely, pazopanib, a cancer therapy drug, may have non-pharmacokinetic interactions with the HFE gene by affecting iron metabolic pathways, though the exact mechanism is less clear.

**HCP5**: HCP5 plays a crucial role in pharmacogenetics, specifically interacting with abacavir, a drug used in HIV treatment. The hypersensitivity to abacavir is linked to the HCP5-related rs2395029 polymorphism, which affects the expression of the HLA-B*5701 allele, necessitating genetic testing before prescribing the drug to avoid severe adverse reactions. While there are potential interactions with other immune-modulating drugs, such as flucloxacillin and gemcitabine, these are not as clearly defined as the interaction with abacavir.

**RRM1**: RRM1 expression significantly influences the effectiveness of certain chemotherapy drugs; high levels of the RRM1 gene confer resistance to gemcitabine, which is used in various cancers including pancreatic and breast cancer. Conversely, lower RRM1 levels enhance responsiveness to gemcitabine, particularly in non-small cell lung cancer (NSCLC). RRM1 also affects the pharmacokinetics of ara-CTP in leukemia treatment and potentially impacts responses to other drugs like carboplatin and cladribine, suggesting that RRM1 expression and activity should be considered in tailoring chemotherapy to improve outcomes and minimize toxicity.

**ADORA2A-AS1**: The gene ADORA2A-AS1, encoding the antisense RNA of ADORA2A, indirectly influences the effectiveness of drugs targeting the adenosine A2a receptor by modulating the receptor's expression. Among these, caffeine, an antagonist of the A2a receptor, can have altered stimulatory effects due to changes in ADORA2A expression mediated by ADORA2A-AS1, while the connection between ADORA2A-AS1 and methotrexate's effects is less certain and speculative.

**C18orf56**: C18orf56, a gene with an unclear function, is speculated to potentially interact with drugs predominantly used in cancer treatment (such as prednisone, daunorubicin, epirubicin, vincristine, cytarabine, fluorouracil, capecitabine, methotrexate, and mercaptopurine) and might be involved in drug metabolism or resistance. Additionally, it may also interact with drugs used in autoimmune conditions (like asparaginase, hydroxychloroquine, sulfasalazine, azathioprine, and folic acid), potentially affecting immune responses or cell growth pathways, but these interactions remain unestablished and speculative.

**C5orf56**: C5orf56, a gene implicated in inflammatory and autoimmune processes, might affect the response to drugs such as hydrochlorothiazide through pharmacodynamic interactions relating to its role in inflammation, rather than through alterations in drug metabolism. These potential interactions, which are yet speculative, suggest that C5orf56 could modulate the effects of hydrochlorothiazide on blood pressure and cardiovascular health via immune modulation or inflammation.

**HLA-DQB1**: HLA-DQB1 gene variants significantly impact drug hypersensitivity reactions, particularly for drugs like abacavir, allopurinol, nevirapine, lamotrigine, and carbamazepine, which can cause severe reactions such as Steven-Johnson syndrome and toxic epidermal necrolysis in genetically predisposed individuals. These interactions emphasize the role of HLA-DQB1 in pharmacodynamics, affecting drug safety and efficacy rather than drug metabolism.

**DCK**: Deoxycytidine Kinase (DCK) is fundamental in the metabolism of anticancer drugs like gemcitabine and cytarabine, as variations in the DCK gene affect the transformation of these drugs into their active forms, pivotal for their effectiveness and potential resistance in cancer treatment. For gemcitabine and the ara-CTP metabolite of cytarabine, DCK facilitates their activation through phosphorylation processes, influencing drug efficacy and toxicity in treatments for cancers such as pancreatic, breast, non-small cell lung cancers, and leukemias.

**SLCO1A2**: The gene SLCO1A2 significantly affects the pharmacokinetics of drugs like rocuronium, imatinib, and methotrexate by mediating their hepatic uptake, which alters their effectiveness, safety, and systemic clearance. Rocuronium's performance in anesthesia, imatinib's therapeutic outcomes in cancer treatment, and methotrexate's response in treating malignancies and autoimmune disorders are all influenced by variations in SLCO1A2 activity, impacting their hepatic clearance and overall drug dynamics.

**HLA-DRA**: The HLA-DRA gene, though not directly interacting with drugs through pharmacokinetic pathways, plays an indirect role in pharmacodynamics due to its involvement in the immune system. It is implicated in the immune-mediated drug reactions, such as hypersensitivities to antibiotics like amoxicillin, flucloxacillin, and clavulanate, possibly by affecting how drug-related antigens are presented to the immune system by antigen-presenting cells, thereby influencing the likelihood or severity of allergic reactions.

**RUNDC3B**: Although the gene RUNDC3B is primarily involved in intracellular trafficking, its potential pharmacogenetic interaction with imatinib, a tyrosine kinase inhibitor used in cancer treatment, remains speculative. Given RUNDC3B's role in cellular dynamics, there is a possibility that it could influence the intracellular concentration and efficacy of imatinib in cancer cells, particularly those with varying expressions of RUNDC3B; however, this interaction lacks concrete evidence and is still under exploration.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**MLN**: Carbamazepine might affect gastrointestinal motility indirectly through its impact on neural pathways rather than by directly interacting with the motilin pathways encoded by the MLN gene. Drugs like macrolide antibiotics, however, are used to directly target motilin receptors to treat conditions such as gastroparesis, with their effectiveness and safety often influenced by individual genetic variations in the MLN gene or its receptors.

**DCTD**: The gene DCTD, which encodes deoxycytidylate deaminase involved in DNA synthesis, impacts the effectiveness and toxicity of cancer chemotherapy drugs like cytarabine and gemcitabine. Variants in DCTD can influence the metabolism and bioavailability of these drugs, directly affecting cytarabine by altering the conversion of its metabolites and possibly influencing gemcitabine's efficacy related to cellular nucleotide pools.

**ABCC5**: ABCC5, an efflux transporter gene, influences the pharmacokinetics and pharmacodynamics of several drugs, notably altering the bioavailability and systemic toxicity of doxorubicin, a key cancer chemotherapy drug. Other drugs such as glyburide, leucovorin, cannabidiol, irinotecan, and fluorouracil are also likely affected by ABCC5's capacity to modulate drug levels, either impacting their therapeutic efficacy or altering their toxicity profile.

**IGF2-AS**: The IGF2-AS gene, by modulating IGF2 expression through its antisense RNA, influences the effectiveness and safety of drugs like growth hormone replacements and insulin therapies which target the insulin-like growth factor pathway. Alterations in IGF2-AS can lead to varied responses to these treatments, necessitating adjustments in drug dosages and approaches to maximize efficacy and minimize adverse effects in conditions like growth hormone deficiencies and diabetes.

**SLC22A11**: The gene SLC22A11 encodes for the organic anion transporter 4 (OAT4), which significantly impacts the renal excretion of drugs such as diuretics like furosemide and thiazide, influencing their effectiveness and potential for toxicity. Alterations in SLC22A11 also affect the clearance of methotrexate, a chemotherapeutic and immunosuppressant agent, primarily through modified drug transport, which could lead to changes in its pharmacokinetic profile despite not directly influencing its metabolism.

**TAPBP**: The gene TAPBP, which is crucial in the antigen presentation pathway, does not show a direct pharmacogenetic interaction with aspirin. Aspirin's primary action involves inhibiting COX enzymes to reduce inflammation and thrombosis, and any possible connection with TAPBP would be more about general immunomodulatory effects rather than direct interactions with the gene's protein product.

**GBP6**: The gene GBP6, which plays a role in immune response particularly related to interferons, is theorized to affect the pharmacodynamics of drugs like interferons used in treating hepatitis and certain cancers. Although unproven, GBP6's function might alter the effectiveness of such drugs by influencing anti-viral defense mechanisms, suggesting a potential interaction with any therapies targeting or influenced by interferon pathways.

**HLA-DPB1**: HLA-DPB1, a gene expressed in antigen-presenting cells, primarily affects drug hypersensitivity reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) through immune modulation, particularly in pharmacodynamic interactions. For example, its specific alleles may increase the risk of agranulocytosis in patients treated with the antipsychotic drug clozapine, while there is no confirmed pharmacogenetic interaction between HLA-DPB1 and aspirin.

**ADA**: ADA (Adenosine Deaminase) plays a critical role in purine metabolism that affects the pharmacokinetics and pharmacodynamics of several drugs. Specifically, ADA interacts pharmacogenetically with Pegademase bovine (Adagen) to treat ADA-linked Severe Combined Immunodeficiency (SCID) by compensating for the lack of ADA activity and improving clinical outcomes. Furthermore, drugs like azathioprine and 6-mercaptopurine, as well as methotrexate, also interact with ADA, influencing their efficacy and toxicity through mechanisms linked to ADA's enzymatic or cellular metabolic roles.

**SLC29A2**: SLC29A2, as an equilibrative nucleoside transporter 2 (ENT2), is essential for the pharmacokinetics of nucleoside analog drugs such as cladribine, used in treatments like hairy cell leukemia. Genetic variability in SLC29A2 can impact the absorption and elimination of these drugs, affecting their efficacy and safety by altering drug uptake and leading to varied therapeutic outcomes or adverse effects in patients.

**LILRB5**: LILRB5, an immunomodulatory gene expressed in cells like monocytes and natural killer cells, currently has no established pharmacogenetic interactions with specific drugs, but its role as an inhibitory receptor suggests it could potentially influence the effectiveness of drugs that modulate immune responses. This impact would predominantly affect pharmacodynamics by altering immune cell behavior, particularly in therapies targeting cancer or autoimmune diseases.

**HLA-DRB5**: HLA-DRB5 affects the pharmacogenetics of clavulanate, amoxicillin, and clozapine by modulating immune responses rather than altering drug metabolism or transport. In the cases of clavulanate and amoxicillin, this can lead to hypersensitivity reactions, while for clozapine, it can influence the risk of agranulocytosis, all due to variations in HLA-DRB5 that affect the immune system's reaction to these drugs.

**ABCC11**: The ABCC11 gene, known for facilitating ATP-dependent transport across cellular membranes, significantly affects the pharmacokinetics of anticancer drugs like fluorouracil and capecitabine by varying the efficiency of drug metabolite expulsion from cells. Different ABCC11 genetic variants lead to changes in drug bioavailability and toxicity, which affects the efficacy and side effects experienced by patients, making it pivotal for customizing cancer treatment protocols.

**SLC28A2**: SLC28A2 plays a crucial role in the transport of nucleoside and nucleoside analog drugs into cells, impacting their absorption, efficacy, and side effects. Variants of the SLC28A2 gene can alter the pharmacokinetics and effectiveness of drugs like ribavirin, gemcitabine, tenofovir disoproxil fumarate, mercaptopurine, and methotrexate, leading to significant variations in therapeutic outcomes and toxicity profiles.
